Please use this identifier to cite or link to this item:
Title: An update on focal therapy for prostate cancer
Austin Authors: Perera, Marlon ;Krishnananthan, Nishanth;Lindner, Uri;Lawrentschuk, Nathan
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Urology, Kaplan Medical Centre, Pasternak Street, Rehovot, Israel
Department of Surgical Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Issue Date: Nov-2016
Date: 2016-09-27
Publication information: Nature Reviews Urology 2016; 13(11): 641-653
Abstract: Globally, the increased uptake of serum PSA level screening led to an increase in the number of diagnoses of low-risk and intermediate-risk prostate cancer. Traditionally, these patients have been considered for either active surveillance programmes or radical whole-gland therapies, such as prostatectomy or radiotherapy. Focal therapy is an emerging treatment option that involves the focal ablation of prostate cancer with preservation of surrounding healthy tissue. This approach might result in reduced morbidity when compared with whole-gland therapies. In current practice, much controversy surrounds optimal patient selection and preoperative tumour localization strategies. Focal therapy modalities include cryotherapy, high-intensity focused ultrasound, laser ablation, photodynamic therapy, irreversible electroporation, radiofrequency ablation and focal brachytherapy. However, as long-term oncological data for focal therapies are lacking, formal recommendations for its use cannot be made.
DOI: 10.1038/nrurol.2016.177
ORCID: 0000-0001-8553-5618
Journal: Nature Reviews Urology
PubMed URL:
Type: Journal Article
Subjects: Prostate cancer
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 24, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.